Hyperglycemia News and Research

RSS
Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.
Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

Bitter cumin contains high levels of antioxidants and protects against DNA damage

Bitter cumin contains high levels of antioxidants and protects against DNA damage

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

China's SFDA approves TPI anti-diabetic drug Gliclazide

China's SFDA approves TPI anti-diabetic drug Gliclazide

Millennium submits two VELCADE sNDAs to FDA

Millennium submits two VELCADE sNDAs to FDA

PVT1 gene may help reduce diabetic nephropathy

PVT1 gene may help reduce diabetic nephropathy

Diabetes in Control publishes complete list of drugs that affect blood glucose

Diabetes in Control publishes complete list of drugs that affect blood glucose

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Walking slows progression of nonalcoholic fatty liver disease in obese people

Walking slows progression of nonalcoholic fatty liver disease in obese people

Experts to discuss about links between metabolic function and disease at EB2011

Experts to discuss about links between metabolic function and disease at EB2011

New medical guidelines for diabetes care

New medical guidelines for diabetes care

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown

ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.